May 1, 2000
Bert Vogelstein, M.D., Clayton Professor of Oncology at Johns Hopkins and Investigator, Howard Hughes Medical Institute will receive the General Motors Cancer Research Foundation Charles S. Mott Prize which honors the most outstanding recent contributions to the discovery of the causes or prevention of cancer. With the award, Dr. Vogelstein will receive a $250,000 prize.
Dr. Vogelstein is a leading international expert and pioneer in the field of molecular genetics. His expertise in using the exquisitely sensitive tools of molecular biology has led to the discovery of a series of genetic mutations that cause the initiation and progression of colon cancer. Among his discoveries are the role of the p53 gene in cancer, now considered the most commonly mutated gene among all cancers; the APC gene, linked to familial adenomatous polyposis (FAP) and familial colon cancer (FCC); and several mismatch repair genes involved in the onset of hereditary non-polyposis colon cancer (HNPCC). Key papers on colon cancer published by Dr. Vogelstein over the last two decades have made him the most highly cited scientist in the world. Most recently, Dr. Vogelstein and colleagues have developed a new technology to improve the accuracy of genetic tests for certain hereditary diseases.
A Baltimore native, he received his medical degree from Johns Hopkins in 1974 where he also completed his internship and residency. He joined Hopkins faculty in 1978.
The General Motors Cancer Research Foundation was established to recognize outstanding contributions in cancer research including, basic science, epidemiology, prevention, diagnosis and treatment. Prize recipients are selected by a panel of internationally prominent basic and clinical scientists. Charles S. Mott, a long tenured General Motors Corporation officer and Director, was a generous public benefactor who made significant contributions toward the improvement of health care. Dr. Vogelstein will receive his award at a ceremony that concludes a scientific conference sponsored by the General Motors Cancer Research Foundation on June 6-7 at the National Institutes of Health in Bethesda, Md.